Jazz Pharmaceuticals JAZZ Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's operating lease liabilities?
- Jazz Pharmaceuticals (JAZZ) reported operating lease liabilities of $47.3M in Q1 2026.
- How has Jazz Pharmaceuticals's operating lease liabilities changed year-over-year?
- Jazz Pharmaceuticals's operating lease liabilities increased by 22.0% year-over-year, from $38.78M to $47.3M.
- What is the long-term trend for Jazz Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's operating lease liabilities has grown at a -18.3% compound annual growth rate (CAGR), from $140.04M to $50.9M.
- What does operating lease liabilities mean?
- The long-term portion of future lease payments for rented assets.
- How do you interpret operating lease liabilities?
- An increase suggests expansion of physical footprint or new long-term equipment leasing, while a decrease indicates lease expirations or downsizing.
- How does operating lease liabilities compare across companies?
- Standardized across companies with significant real estate or equipment lease portfolios.